Cited by 1,860HER2/EGFR in Cancer ResearchGastric Cancer Management and OutcomesLung Cancer Treatments and Mutations

The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.

Efficacy and Safety of Trastuzumab as a Single Agent in First-Line Treatment of HER2-Overexpressing Metastatic Breast Cancer

Vogel, Charles L., Cobleigh, Melody A., Tripathy, Debu, Gutheil, John C., Harris, Lyndsay N., Fehrenbacher, Louis, Slamon, Dennis J., Murphy, Maureen, Novotny, William F., Burchmore, Michael, Shak, Steven, Stewart, Stanford J., Press, Michael·2002·Journal of Clinical Oncology

DOI 10.1200/jco.2002.20.3.719

Open this paper in CoChat — free account

Abstract

PURPOSE: To evaluate the efficacy and safety of first-line, single-agent trastuzumab in women with HER2-overexpressing metastatic breast cancer. PATIENTS AND METHODS: One hundred fourteen women with HER2-overexpressing metastatic breast cancer were randomized to receive first-line treatment with trastuzumab 4 mg/kg loading dose, followed by 2 mg/kg weekly, or a higher 8 mg/kg loading dose, followed by 4 mg/kg weekly. RESULTS: The objective response rate was 26% (95% confidence interval [CI], 18.2% to 34.4%), with seven complete and 23 partial responses. Response rates in 111 assessable patients with 3+ and 2+ HER2 overexpression by immunohistochemistry (IHC) were 35% (95% CI, 24.4% to 44.7%) and none (95% CI, 0% to 15.5%), respectively. The clinical benefit rates in assessable patients with 3+ and 2+ HER2 overexpression were 48% and 7%, respectively. The response rates in 108 assessable patients with and without HER2 gene amplification by fluorescence in situ hybridization (FISH) analysis were 34% (95% CI, 23.9% to 45.7%) and 7% (95% CI, 0.8% to 22.8%), respectively. Seventeen (57%) of 30 patients with an objective response and 22 (51%) of 43 patients with clinical benefit had not experienced disease progression at follow-up at 12 months or later. The most common treatment-related adverse events were chills (25% of patients), asthenia (23%), fever (22%), pain (18%), and nausea (14%). Cardiac dysfunction occurred in two patients (2%); both had histories of cardiac disease and did not require additional intervention after discontinuation of trastuzumab. There was no clear evidence of a dose-response relationship for response, survival, or adverse events. CONCLUSION: Single-agent trastuzumab is active and well tolerated as first-line treatment of women with metastatic breast cancer with HER2 3+ overexpression by IHC or gene amplification by FISH.

Integrity signals

Registry

Crossref · 10.1200/jco.2002.20.3.719

Cites

9 of 9 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

The European Organization for Research and Treatment of Cancer QLQ-C30: A Quality-of-Life Instrument for Use in International Clinical Trials in Oncology
Aaronson, N. K., Ahmedzai, S., Bergman, B., Bullinger, M., Cull, A., Duez, N. J., Filiberti, A., Flechtner, H., Fleishman, S. B., Haes, J. C. J. M. D., et al. (1993) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/85.5.365 · Cited by 16,005
Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/ neu Oncogene
Slamon, D. J., Clark, G. M., Wong, S. G., Levin, W. J., Ullrich, A., & McGuire, W. L. (1987) · Science · doi:10.1126/science.3798106 · Cited by 11,760
Self-citation
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2
Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103153441101 · Cited by 11,500
Self-citation
Studies of the HER-2/ neu Proto-Oncogene in Human Breast and Ovarian Cancer
Slamon, D. J., Godolphin, W. J., Jones, L. A., Holt, J. A., Wong, S., Keith, D. E., Levin, W. J., Stuart, S. G., Udove, J. A., Ullrich, A., et al. (1989) · Science · doi:10.1126/science.2470152 · Cited by 6,817
Self-citation
Multinational Study of the Efficacy and Safety of Humanized Anti-HER2 Monoclonal Antibody in Women Who Have HER2-Overexpressing Metastatic Breast Cancer That Has Progressed After Chemotherapy for Metastatic Disease
Cobleigh, M., Vogel, C. L., Tripathy, D., Robert, N. J., Scholl, S., Fehrenbacher, L., Wolter, J. M., Paton, V. E., Shak, S., Lieberman, G., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.9.2639 · Cited by 2,767
Self-citation
Humanization of an anti-p185HER2 antibody for human cancer therapy.
Carter, P. M., Presta, L. G., Gorman, C., Ridgway, J. B., Henner, D. J., Wong, W., Rowland, A. M., Kotts, C. E., Carver, M. E., & Shepard, H. M. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.10.4285 · Cited by 1,926
The biology of erbB-2/nue/HER-2 and its role in cancer
Hynes, N. E. (1994) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/0304-419x(94)90012-4 · Cited by 974
The c-erbB-2 proto-oncogene as a prognostic and predictive marker in breast cancer: A paradigm for the development of other macromolecular markers-A review
Ravdin, P. M., & Chamness, G. C. (1995) · Gene · doi:10.1016/0378-1119(94)00866-q · Cited by 250
c-erbB-2 oncoprotein expression in primary and advanced breast cancer
Lovekin, C., Ellis, I. O., Locker, A. P., Robertson, J., Bell, J., Nicholson, R., Gullick, W., Elston, C., & Blamey, R. W. (1991) · British Journal of Cancer · doi:10.1038/bjc.1991.101 · Cited by 237

Flagged first, then by citations

Show all 9 references

Sorted by citations

Items 501–600 of 1,009

The emerging importance of α-L-fucose in human breast cancer: a review.
Listinsky, J. J., Siegal, G. P., & Listinsky, C. M. (2011) · PubMed Central · Cited by 65
Assessment of Her-1, Her-2, and Her-3 Expression and Her-2 Amplification in Advanced Stage Ovarian Carcinoma
Lee, C., Huntsman, D. D., Cheang, M. C. U., Parker, R. L., Brown, L. A., Hoskins, P. J., Miller, D. M., & Gilks, C. B. (2005) · International Journal of Gynecological Pathology · doi:10.1097/01.pgp.0000152026.39268.57 · Cited by 65
Molecular Mechanisms and Translational Therapies for Human Epidermal Receptor 2 Positive Breast Cancer
Lv, Q., Meng, Z., Yu, Y., Jiang, F., Guan, D., Liang, C., Zhou, J., Lü, A., & Zhang, G. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17122095 · Cited by 66
Preclinical Targeted α- and β−-Radionuclide Therapy in HER2-Positive Brain Metastasis Using Camelid Single-Domain Antibodies
Puttemans, J., Dekempeneer, Y., Eersels, J. L. H., Hanssens, H., Debie, P., Keyaerts, M., Windhorst, A. D., van der Aa, F., Lecocq, Q., Breckpot, K., et al. (2020) · Cancers · doi:10.3390/cancers12041017 · Cited by 64
Biology-Driven Phase II Trials: What Is the Optimal Model for Molecular Selection?
André, F., Delaloge, S., & Soria, J. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.31.6877 · Cited by 65
Long Non-Coding RNA: Dual Effects on Breast Cancer Metastasis and Clinical Applications
Huang, Q.-Y., Liu, G., Qian, X., Tang, L.-B., Huang, Q.-Y., & Xiong, L. (2019) · Cancers · doi:10.3390/cancers11111802 · Cited by 64
A New Rabbit Monoclonal Antibody (4B5) for the Immunohistochemical (IHC) Determination of the HER2 Status in Breast Cancer: Comparison With CB11, Fluorescence In Situ Hybridization (FISH), and Interlaboratory Reproducibility
Powell, W. C., Hicks, D. G., Prescott, N. L., Tarr, S. M., Laniauskas, S., Williams, T., Short, S., Pettay, J., Nagle, R. B., Dabbs, D. J., et al. (2007) · Applied immunohistochemistry & molecular morphology · doi:10.1097/pai.0b013e31802ced25 · Cited by 65
Targeted Therapy in the Management of Advanced Gastric Cancer: Are We Making Progress in the Era of Personalized Medicine?
Wong, H., & Yau, T. C. C. (2012) · The Oncologist · doi:10.1634/theoncologist.2011-0311 · Cited by 65
Phase II Study of Celecoxib and Trastuzumab in Metastatic Breast Cancer Patients Who Have Progressed after Prior Trastuzumab-Based Treatments
Dang, C. T., Dannenberg, A. J., Subbaramaiah, K., Dickler, M. N., Moasser, M. M., Seidman, A. D., D’Andrea, G. M., Theodoulou, M., Panageas, K. S., Norton, L., et al. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0463 · Cited by 64
Monoclonal Antibodies, Small Molecules, and Vaccines in the Treatment of Breast Cancer
Esteva, F. J. (2004) · The Oncologist · doi:10.1634/theoncologist.9-suppl_3-4 · Cited by 64
Viruses – seeking and destroying the tumor program
O’Shea, C. C. (2005) · Oncogene · doi:10.1038/sj.onc.1209047 · Cited by 65
Trastuzumab resistance induces EMT to transform HER2+ PTEN− to a triple negative breast cancer that requires unique treatment options
Burnett, J., Körkaya, H., Ouzounova, M., Jiang, H., Conley, S. J., Newman, B. W., Sun, L., Connarn, J. N., Chen, C., Zhang, N., et al. (2015) · Scientific Reports · doi:10.1038/srep15821 · Cited by 64
A Mechanistic Study of Tumor-Targeted Corrole Toxicity
Hwang, J. Y., Lubow, J., Chu, D., Ma, J., Agadjanian, H., Sims, J. D., Gray, H. B., Gross, Z., Farkas, D. L., & Medina‐Kauwe, L. K. (2011) · Molecular Pharmaceutics · doi:10.1021/mp200094w · Cited by 63
Development of the Novel Biologically Targeted Anticancer Agent Gefitinib
Wolf, M., Swaisland, H., & Averbuch, S. D. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0058 · Cited by 63
Activation of STAT3/HIF-1α/Hes-1 axis promotes trastuzumab resistance in HER2-overexpressing breast cancer cells via down-regulation of PTEN
Aghazadeh, S., & Yazdanparast, R. (2017) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2017.05.009 · Cited by 64
Phase II study of buparlisib (BKM120) and trastuzumab in patients with HER2+ locally advanced or metastatic breast cancer resistant to trastuzumab-based therapy
Pistilli, B., Pluard, T., Urruticoechea, A., Farci, D., Kong, A., Bachelot, T., Chan, S., Han, H., Jerusalem, G., Urban, P., et al. (2017) · Breast Cancer Research and Treatment · doi:10.1007/s10549-017-4596-7 · Cited by 53
RETRACTED ARTICLE: Targeting 17q23 amplicon to overcome the resistance to anti-HER2 therapy in HER2+ breast cancer
Liu, Y., Xu, J., Choi, H. H., Han, C., Fang, Y., Li, Y., der Jeught, K. V., Xu, H., Zhang, L., Frieden, M., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-07264-0 · Cited by 62
Retracted
Palliative chemotherapy: oxymoron or misunderstanding?
Roeland, E. J., & LeBlanc, T. W. (2016) · BMC Palliative Care · doi:10.1186/s12904-016-0109-4 · Cited by 61
Conformational HER-2/neu B-cell Epitope Peptide Vaccine Designed to Incorporate Two Native Disulfide Bonds Enhances Tumor Cell Binding and Antitumor Activities
Dakappagari, N. K., Lute, K. D., Rawale, S. V., Steele, J. T., Allen, S. D., Phillips, G. S., Reilly, R. T., & Kaumaya, P. T. P. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m411020200 · Cited by 62
Phase II Study of Lapatinib in Combination With Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer: Clinical Outcomes and Predictive Value of Early [18F]Fluorodeoxyglucose Positron Emission Tomography Imaging (TBCRC 003)
Lin, N., Guo, H., Yap, J. T., Mayer, I. A., Falkson, C. I., Hobday, T. J., Dees, E. C., Richardson, A. L., Nanda, R., Rimawi, M. F., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.60.0353 · Cited by 63
Breast Cancer Therapeutics and Biomarkers: Past, Present, and Future Approaches
Schick, J., Ritchie, R. P., & Restini, C. B. A. (2021) · Breast Cancer Basic and Clinical Research · doi:10.1177/1178223421995854 · Cited by 64
Her-2/neu-triggered intracellular tyrosine kinase activation: in vivo relevance of ligand-independent activation mechanisms and impact upon the efficacy of trastuzumab-based treatment
Hudelist, G., Köstler, W. J., Attems, J., Czerwenka, K. F., Müller, R., Manavi, M., Steger, G. G., Kubista, E., Zielinski, C. C., & Singer, C. F. (2003) · British Journal of Cancer · doi:10.1038/sj.bjc.6601160 · Cited by 62
Resistance to Trastuzumab: A Necessary Evil or a Temporary Challenge?
Cardoso, F., Piccart, M. J., Durbecq, V., & Leo, A. D. (2002) · Clinical Breast Cancer · doi:10.3816/cbc.2002.n.028 · Cited by 61
HER2 expression on tumor-derived extracellular vesicles and circulating tumor cells in metastatic breast cancer
Nanou, A., Zeune, L. L., Bidard, F., Pierga, J., & Terstappen, L. W. M. M. (2020) · Breast Cancer Research · doi:10.1186/s13058-020-01323-5 · Cited by 61
Human Epidermal Growth Factor Receptor Family-Targeted Therapies in the Treatment of HER2-Overexpressing Breast Cancer
Eroglu, Z., Tagawa, T., & Somlo, G. (2014) · The Oncologist · doi:10.1634/theoncologist.2013-0283 · Cited by 62
A Synthetic Glycopeptide Vaccine for the Induction of a Monoclonal Antibody that Differentiates between Normal and Tumor Mammary Cells and Enables the Diagnosis of Human Pancreatic Cancer
Palitzsch, B., Gaidzik, N., Stergiou, N., Stahn, S., Hartmann, S., Gerlitzki, B., Teusch, N. E., Flemming, P., Schmitt, E., & Kunz, H. (2016) · Angewandte Chemie International Edition · doi:10.1002/anie.201509935 · Cited by 61
TRIM14 Promotes Breast Cancer Cell Proliferation by Inhibiting Apoptosis
Hu, G., Pen, W., & Wang, M. (2018) · Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics · doi:10.3727/096504018x15214994641786 · Cited by 61
Standardization of HER2 Immunohistochemistry in Breast Cancer by Automated Quantitative Analysis
Gustavson, M. D., Bourke-Martin, B., Reilly, D., Cregger, M. A., Williams, C., Mayotte, J., Zerkowski, M. P., Tedeschi, G., Pinard, R., & Christiansen, J. (2009) · Archives of Pathology & Laboratory Medicine · doi:10.5858/133.9.1413 · Cited by 61
Therapeutic options for metastatic breast cancer
Morris, P. G., McArthur, H. L., & Hudis, C. A. (2009) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656560902834961 · Cited by 59
Developmental pathways in breast cancer and breast tumor-initiating cells: Therapeutic implications
Izrailit, J., & Reedijk, M. (2011) · Cancer Letters · doi:10.1016/j.canlet.2011.11.028 · Cited by 62
A proposal for diagnostically meaningful criteria to classify increased epidermal growth factor receptor and c-erbB-2 gene copy numbers in gastric carcinoma, based on correlation of fluorescence in situ hybridization and immunohistochemical measurements
木村, 幹., Tsuda, H., Morita, D., Ichikura, T., Ogata, S., Aida, S., Yoshizumi, Y., Maehara, T., Mochizuki, H., & Matsubara, O. (2004) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-004-1048-7 · Cited by 60
Trastuzumab-Functionalized Nanoparticles of Biodegradable Copolymers for Targeted Delivery of Docetaxel
Sun, B., & Feng, S. (2009) · Nanomedicine · doi:10.2217/nnm.09.17 · Cited by 60
Targeting Signal Transduction Pathways in Metastatic Breast Cancer: A Comprehensive Review
Rosen, L. S., Ashurst, H. L., & Chap, L. I. (2010) · The Oncologist · doi:10.1634/theoncologist.2009-0145 · Cited by 62
Nonpegylated Liposomal Doxorubicin (TLC-D99), Paclitaxel, and Trastuzumab in HER-2-Overexpressing Breast Cancer: A Multicenter Phase I/II Study
Cortés, J., Cosimo, S. D., Climent, M. A., Cortés-Funes, H., Lluch, A. M., Gascón, P., Mayordomo, J. I., Gil, M. G., Benavides, M., Cirera, L., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1113 · Cited by 60
Central Nervous System Metastases in HER-2–Overexpressing Metastatic Breast Cancer: A Treatment Challenge
Stemmler, H., & Heinemann, V. (2008) · The Oncologist · doi:10.1634/theoncologist.2008-0052 · Cited by 60
Advances in bovine serum albumin-protected gold nanoclusters: from understanding the formation mechanisms to biological applications
Chen, L., Gharib, M., Zeng, Y., Roy, S., Nandi, C. K., & Chakraborty, I. (2023) · Materials Today Chemistry · doi:10.1016/j.mtchem.2023.101460 · Cited by 59
Personalized Medicine and the Practice of Medicine in the 21st Century
Issa, A. M. (2020) · McGill Journal of Medicine · doi:10.26443/mjm.v10i1.625 · Cited by 59
Continuing trastuzumab beyond disease progression: outcomes analysis in patients with metastatic breast cancer
Cancello, G., Montagna, E., D’Agostino, D., Giuliano, M., Giordano, A., Lorenzo, G. D., Plaitano, M., Placido, S. D., & Laurentiis, M. D. (2008) · Breast Cancer Research · doi:10.1186/bcr2119 · Cited by 59
A mechanistic pan-cancer pathway model informed by multi-omics data interprets stochastic cell fate responses to drugs and mitogens
Bouhaddou, M., Barrette, A. M., Stern, A. D., Koch, R. J., DiStefano, M. S., Riesel, E. A., Santos, L. C., Tan, A. L., Mertz, A. E., & Birtwistle, M. R. (2018) · PLOS Computational Biology · doi:10.1371/journal.pcbi.1005985 · Cited by 58
FAM83 proteins: Fostering new interactions to drive oncogenic signaling and therapeutic resistance
Bartel, C. A., Parameswaran, N., Cipriano, R., & Jackson, M. W. (2016) · Oncotarget · doi:10.18632/oncotarget.9544 · Cited by 57
Integrating molecular diagnostics into anticancer drug discovery
Peták, I., Schwab, R. E., Őrfi, L., Kopper, L., & Kéri, G. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3135 · Cited by 58
Brain metastases in Asian HER2-positive breast cancer patients: anti-HER2 treatments and their impact on survival
Yap, Y. S., Cornelio, G. H., Devi, B. C. R., Khorprasert, C., Kim, S.-B., Kim, T. Y., Lee, S. C., Park, Y. H., Sohn, J., Sutandyo, N., et al. (2012) · British Journal of Cancer · doi:10.1038/bjc.2012.346 · Cited by 58
Single-Antibody, Targeted Nanoparticle Delivery of Camptothecin
Han, H., & Davis, M. E. (2013) · Molecular Pharmaceutics · doi:10.1021/mp300702x · Cited by 58
Bispecific Antibody to ErbB2 Overcomes Trastuzumab Resistance through Comprehensive Blockade of ErbB2 Heterodimerization
Li, B., Meng, Y., Zheng, L., Zhang, X., Tong, Q., Tan, W., Hu, S., Li, H., Chen, Y., Song, J., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-13-0657 · Cited by 58
HER-2-Positive Metastatic Breast Cancer: Optimizing Trastuzumab-Based Therapy
Jackisch, C. (2006) · The Oncologist · doi:10.1634/theoncologist.11-90001-34 · Cited by 58
Transforming Growth Factor α Expression Drives Constitutive Epidermal Growth Factor Receptor Pathway Activation and Sensitivity to Gefitinib (Iressa) in Human Pancreatic Cancer Cell Lines
Pino, M. S., Shrader, M., Baker, C. H., Cognetti, F., Xiong, H. Q., Abbruzzese, J. L., & McConkey, D. J. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-3753 · Cited by 58
Inhibition of tumor cell growth by antibodies induced after vaccination with peptides derived from the extracellular domain of Her‐2/neu
Jasińska, J., Wagner, S. N., Radauer, C., Sedivy, R., Brodowicz, T., Wiltschke, C., Breiteneder, H., Pehamberger, H., Scheiner, O., Wiedermann, U., et al. (2003) · International Journal of Cancer · doi:10.1002/ijc.11485 · Cited by 58
Redox Potential Ultrasensitive Nanoparticle for the Targeted Delivery of Camptothecin to HER2-Positive Cancer Cells
Remant Bahadur, K. C., Chandrashekaran, V., Cheng, B., Chen, H., Peña, M. M. O., Zhang, J., Montgomery, J., & Xu, P. (2014) · Molecular Pharmaceutics · doi:10.1021/mp5000482 · Cited by 57
Neuregulin 1 Expression Is a Predictive Biomarker for Response to AV-203, an ERBB3 Inhibitory Antibody, in Human Tumor Models
Meetze, K. A., Vincent, S., Tyler, S. M., Mazsa, E. K., Delpero, A. R., Bottega, S., McIntosh, D., Nicoletti, R., Winston, W. M., Weiler, S., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2407 · Cited by 56
Autoantibodies as Potential Biomarkers in Breast Cancer
Qiu, J., Keyser, B., Lin, Z., & Wu, T. (2018) · Biosensors · doi:10.3390/bios8030067 · Cited by 56
A phase II study of trastuzumab and capecitabine for patients with HER2-overexpressing metastatic breast cancer: Japan Breast Cancer Research Network (JBCRN) 00 Trial
Yamamoto, D., Iwase, S., Kitamura, K., Odagiri, H., Yamamoto, C., & Nagumo, Y. (2007) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-007-0497-5 · Cited by 57
Trastuzumab-DM1: Building a Chemotherapy-Free Road in the Treatment of Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer
Isakoff, S. J., & Baselga, J. M. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.31.6679 · Cited by 57
Trastuzumab-Coated Nanoparticles Loaded With Docetaxel for Breast Cancer Therapy
Zhang, X., Liu, J., Li, X., Li, F., Lee, R. J., Sun, F., Li, Y., Liu, Z., & Teng, L. (2019) · Dose-Response · doi:10.1177/1559325819872583 · Cited by 56
HEROHE Challenge: Predicting HER2 Status in Breast Cancer from Hematoxylin–Eosin Whole-Slide Imaging
Conde‐Sousa, E., Vale, J., Feng, M., Xu, K., Wang, Y., Mea, V. D., Barbera, D. L., Montahaei, E., Baghshah, M. S., Turzynski, A., et al. (2022) · Journal of Imaging · doi:10.3390/jimaging8080213 · Cited by 61
Peptides Targeting HER2-Positive Breast Cancer Cells and Applications in Tumor Imaging and Delivery of Chemotherapeutics
Cavallaro, P. A., Santo, M. D., Belsito, E. L., Longobucco, C., Curcio, M., Morelli, C., Pasqua, L., & Leggio, A. (2023) · Nanomaterials · doi:10.3390/nano13172476 · Cited by 60
Therapy Insight: anthracyclines and trastuzumab—the optimal management of cardiotoxic side effects
Popat, S., & Smith, I. E. (2008) · Nature Clinical Practice Oncology · doi:10.1038/ncponc1090 · Cited by 56
Targeted Therapies in Type II Endometrial Cancers: Too Little, but Not Too Late
Remmerie, M., & Janssens, V. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19082380 · Cited by 56
Molecular-targeted therapies and precision medicine for endometrial cancer
Mitamura, T., Dong, P., Ihira, K., 工藤, 正., & Watari, H. (2018) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyy159 · Cited by 56
Current and emerging targeted therapies for metastatic breast cancer
Perez, E. A., & Spano, J. (2011) · Cancer · doi:10.1002/cncr.26356 · Cited by 55
Trastuzumab as Adjuvant Therapy for Early Breast Cancer: The Importance of Accurate Human Epidermal Growth Factor Receptor 2 Testing
Hicks, D. G., & Kulkarni, S. (2008) · Archives of Pathology & Laboratory Medicine · doi:10.5858/2008-132-1008-taatfe · Cited by 55
Heterogeneity of ERBB2 amplification in adenocarcinoma, squamous cell carcinoma and large cell undifferentiated carcinoma of the lung
Grob, T. J., Kannengießer, I., Tsourlakis, M., Atanackovic, D., Koenig, A. M., Vashist, Y. K., Klose, H. F. E., Marx, A. H., Koops, S., Simon, R., et al. (2012) · Modern Pathology · doi:10.1038/modpathol.2012.125 · Cited by 55
X-ray computed tomography imaging of a tumor with high sensitivity using gold nanoparticles conjugated to a cancer-specific antibody via polyethylene glycol chains on their surface
Nakagawa, T., Gonda, K., Kamei, T., Cong, L., Hamada, Y., Kitamura, N., Tada, H., Ishida, T., Aimiya, T., Furusawa, N., et al. (2016) · Science and Technology of Advanced Materials · doi:10.1080/14686996.2016.1194167 · Cited by 55
Neratinib resistance and cross-resistance to other HER2-targeted drugs due to increased activity of metabolism enzyme cytochrome P4503A4
Breslin, S., Lowry, M. C., & O’Driscoll, L. (2017) · British Journal of Cancer · doi:10.1038/bjc.2016.445 · Cited by 53
Breast cancer stem cells are involved in Trastuzumab resistance through the HER2 modulation in 3D culture
Rodriguez, C. E., Berardi, D. E., Abrigo, M., Todaro, L. B., Joffé, E. B. D. K., & Fiszman, G. L. (2017) · Journal of Cellular Biochemistry · doi:10.1002/jcb.26298 · Cited by 55
The emerging role of radionuclide molecular imaging of HER2 expression in breast cancer
Максимилианович, Т. В., Orlova, A., & Sørensen, J. C. H. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.10.005 · Cited by 60
Prostate-Specific Antigen Doubling Time as a Surrogate Marker for Evaluation of Oncologic Drugs to Treat Prostate Cancer
Kelloff, G. J., Coffey, D. S., Chabner, B. A., Dicker, A. P., Guyton, K. Z., Nisen, P. D., Soule, H. R., & D'Amico, A. V. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0788 · Cited by 55
A river model to map convergent cancer evolution and guide therapy in RCC
Wei, E. Y., & Hsieh, J. J.-D. (2015) · Nature Reviews Urology · doi:10.1038/nrurol.2015.260 · Cited by 61
Overexpression of E2F-5 correlates with a pathological basal phenotype and a worse clinical outcome
Umemura, S., Shirane, M., Takekoshi, S., Kusakabe, T., Itoh, J., Egashira, N., Tokuda, Y., Mori, K., & Osamura, Y. R. (2009) · British Journal of Cancer · doi:10.1038/sj.bjc.6604900 · Cited by 52
Antitumor Activity of the Hsp90 Inhibitor IPI-504 in HER2-Positive Trastuzumab-Resistant Breast Cancer
Scaltriti, M., Serra, V., Normant, E., Guzmán, M., Rodríguez, O., Lim, A. R., Slocum, K. L., West, K. A., Rodriguez, V., Prudkin, L., et al. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-10-0966 · Cited by 54
DCZ3112, a novel Hsp90 inhibitor, exerts potent antitumor activity against HER2-positive breast cancer through disruption of Hsp90-Cdc37 interaction
Chen, X., Liu, P., Wang, Q., Li, Y., Li, F., Fu, H., Zhu, J., Chen, Z., Zhu, W., Xie, C., et al. (2018) · Cancer Letters · doi:10.1016/j.canlet.2018.07.012 · Cited by 55
The root cause of drug resistance in HER2-positive breast cancer and the therapeutic approaches to overcoming the resistance
Zhang, Y. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2020.107677 · Cited by 56
Inter-tumor genomic heterogeneity of breast cancers: comprehensive genomic profile of primary early breast cancers and relapses
Fumagalli, C., Ranghiero, A., Gandini, S., Corso, F., Taormina, S. V., Camilli, E. D., Rappa, A., Vacirca, D., Viale, G., Guerini‐Rocco, E., et al. (2020) · Breast Cancer Research · doi:10.1186/s13058-020-01345-z · Cited by 57
Growth factor-induced resistance to tamoxifen is associated with a mutation of estrogen receptor α and its phosphorylation at serine 305
Giordano, C., Cui, Y., Barone, I., Andò, S., Mancini, M. A., Berno, V., & Fuqua, S. A. W. (2009) · Breast Cancer Research and Treatment · doi:10.1007/s10549-009-0334-0 · Cited by 54
Phase II study of weekly paclitaxel and trastuzumab in anthracycline- and taxane-pretreated patients with HER2-overexpressing metastatic breast cancer
Gori, S., Colozza, M., Mosconi, A. M., Franceschi, E., Basurto, C., Cherubini, R., Sidoni, A., Rulli, A., Bisacci, C., Angelis, V. D., et al. (2004) · British Journal of Cancer · doi:10.1038/sj.bjc.6601485 · Cited by 54
Gene expression profiling in breast cancer: towards individualising patient management
Murphy, N., Millar, E. K. A., & Lee, C. (2005) · Pathology · doi:10.1080/00313020500169586 · Cited by 54
HER2-positive breast cancer cells expressing elevated FAM83A are sensitive to FAM83A loss
Bartel, C. A., & Jackson, M. W. (2017) · PLoS ONE · doi:10.1371/journal.pone.0176778 · Cited by 53
The Anticancer Activity of a First-in-class Small-molecule Targeting PCNA
Gu, L., Lingeman, R. G., Yakushijin, F., Sun, E., Cui, Q., Chao, J., Hu, W., Li, H., Hickey, R. J., Stark, J. M., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-0592 · Cited by 57
Gallbladder Cancer: Current Insights in Genetic Alterations and Their Possible Therapeutic Implications
Kuipers, H., de Bitter, T. J. J., de Boer, M. T., van der Post, R. S., Nijkamp, M. W., de Reuver, P. R., Fehrmann, R. S. N., & Hoogwater, F. J. H. (2021) · Cancers · doi:10.3390/cancers13215257 · Cited by 55
Vinorelbine plus trastuzumab combination as first-line therapy for HER 2-positive metastatic breast cancer patients: an international phase II trial
on behalf of the Navelbine® Herceptin® Project, Chan, A., Martín, M., Untch, M., Gil, M., Guillem-Porta, V., Wojtukiewicz, M. Z., Kellokumpu‐Lehtinen, P., Sommer, H. L., Georgoulias, V., et al. (2006) · British Journal of Cancer · doi:10.1038/sj.bjc.6603351 · Cited by 53
Unraveling trastuzumab and lapatinib inefficiency in gastric cancer: Future steps (Review)
Shimoyama, S. (2013) · Molecular and Clinical Oncology · doi:10.3892/mco.2013.218 · Cited by 53
Co-targeting estrogen receptor and HER2 pathways in breast cancer
Mehta, A., & Tripathy, D. (2013) · The Breast · doi:10.1016/j.breast.2013.09.006 · Cited by 55
Self-citation
Cancer-associated fibroblasts induce trastuzumab resistance in HER2 positive breast cancer cells
Mao, Y., Zhang, Y., Qu, Q., Zhao, M., Lou, Y., Liu, J., Huang, O., Chen, X., Wu, J., & Shen, K. (2015) · Molecular BioSystems · doi:10.1039/c4mb00710g · Cited by 53
Protein Kinase A Activation Confers Resistance to Trastuzumab in Human Breast Cancer Cell Lines
Gu, L., Lau, S. K., Loera, S., Somlo, G., & Kane, S. E. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-0585 · Cited by 53
Structural characterization of EGFR exon 19 deletion mutation using molecular dynamics simulation
Tamirat, M. Z., Koivu, M. K. A., Elenius, K., & Johnson, M. S. (2019) · PLoS ONE · doi:10.1371/journal.pone.0222814 · Cited by 53
The genetic complexity of common cancers and the promise of personalized medicine: is there any hope?
Arnedos, M., Vielh, P. R., Soria, J., & André, F. (2013) · The Journal of Pathology · doi:10.1002/path.4276 · Cited by 51
Alternative reagents to antibodies in imaging applications
Bedford, R., Tiede, C., Hughes, R., Curd, A., McPherson, M. J., Peckham, M., & Tomlinson, D. C. (2017) · Biophysical Reviews · doi:10.1007/s12551-017-0278-2 · Cited by 50
Long Non-Coding RNAs as New Master Regulators of Resistance to Systemic Treatments in Breast Cancer
Campos-Parra, A. D., López–Urrutia, E., Moreno, L. T. O., López‐Camarillo, C., Meza‐Menchaca, T., Figueroa‐González, G., Bustamante-Montes, L. P., & Pérez‐Plasencia, C. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19092711 · Cited by 52
Trastuzumab in the management of early and advanced stage breast cancer.
Bartsch, R., Wenzel, C., & Steger, G. G. (2007) · PubMed Central · Cited by 52
Extracellular Matrix 1 (ECM1) Expression Is a Novel Prognostic Marker for Poor Long-Term Survival in Breast Cancer: A Hospital-Based Cohort Study in Iowa
Lal, G., Hashimi, S., Smith, B. J., Lynch, C. F., Zhang, L., Robinson, R. A., & Weigel, R. J. (2009) · Annals of Surgical Oncology · doi:10.1245/s10434-009-0533-2 · Cited by 52
Quantitative HER2 protein levels predict outcome in fluorescence in situ hybridization‐positive patients with metastatic breast cancer treated with trastuzumab
Lipton, A., Köstler, W. J., Leitzel, K. E., Ali, S. M., Sperinde, J., Weidler, J. M., Paquet, A. C., Sherwood, T., Huang, W., Bates, M. P., et al. (2010) · Cancer · doi:10.1002/cncr.25430 · Cited by 54
Clinical importance of HER2 immunohistologic heterogeneous expression in core-needle biopsies vs resection specimens for equivocal (immunohistochemical score 2+) cases
Chivukula, M., Bhargava, R., Brufsky, A., Surti, U., & Dabbs, D. J. (2008) · Modern Pathology · doi:10.1038/modpathol.3801021 · Cited by 52
MKNK1 is a YB-1 target gene responsible for imparting trastuzumab resistance and can be blocked by RSK inhibition
Astanehe, A., Finkbeiner, M., Krzywinski, M. I., Fotovati, A., Dhillon, J., Berquin, I. M., Mills, G. B., Marra, M. A., & Dunn, S. E. (2012) · Oncogene · doi:10.1038/onc.2011.617 · Cited by 52
Incidence, Risk Factors, and Management of Infusion-Related Reactions in Breast Cancer Patients Receiving Trastuzumab
Thompson, L. M., Eckmann, K. R., Boster, B. L., Hess, K. R., Michaud, L. B., Esteva, F. J., Hortobágyi, G. N., & Barnett, C. M. (2014) · The Oncologist · doi:10.1634/theoncologist.2013-0286 · Cited by 52
Targeted therapy in the treatment of solid tumors: Practice contradicts theory
Zhukov, N. V., & Tjulandin, S. A. (2008) · Biochemistry (Moscow) · doi:10.1134/s000629790805012x · Cited by 52
Implications of the Updated 2013 American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations on Human Epidermal Growth Factor Receptor 2 Gene Testing Using Immunohistochemistry and Fluorescence In Situ Hybridization for Breast Cancer
Lim, T. H., Lim, A. S. T., Thike, A. A., Tien, S. L., & Tan, P. H. (2016) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2015-0108-oa · Cited by 52
Progression-free survival as surrogate end point for overall survival in clinical trials of HER2-targeted agents in HER2-positive metastatic breast cancer
Michiels, S., Pugliano, L., Marguet, S., Grun, D., Barinoff, J., Cameron, D., Cobleigh, M., Leo, A. D., Johnston, S. R. D., Gasparini, G. M., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw132 · Cited by 52
Self-citation
Induction of G2M Arrest by Flavokawain A, a Kava Chalcone, Increases the Responsiveness of HER2-Overexpressing Breast Cancer Cells to Herceptin
Jandial, D., Krill, L. S., Chen, L., Wu, C., Ke, Y., Xie, J., Hoang, B. H., & Zi, X. (2017) · Molecules · doi:10.3390/molecules22030462 · Cited by 53
The influence of stage at diagnosis and molecular subtype on breast cancer patient survival: a hospital-based multi-center study
Zuo, T., Zeng, H., Li, H., Liu, S., Yang, L., Xia, C., Zheng, R., Ma, F., Liu, L., Wang, N., et al. (2017) · 癌症：英文版 · doi:10.1186/s40880-017-0250-3 · Cited by 52
Acquired Resistance to HER2-Targeted Therapies Creates Vulnerability to ATP Synthase Inhibition
Gale, M., Li, Y., Cao, J. P., Liu, Z. Z., Holmbeck, M. A., Zhang, M., Lang, S. M., Wu, L., DoCarmo, M., Gupta, S., et al. (2019) · Cancer Research · doi:10.1158/0008-5472.can-18-3985 · Cited by 51
Preclinical activity of sacituzumab govitecan (IMMU-132) in uterine and ovarian carcinosarcomas
Lopez, S., Perrone, E., Bellone, S., Bonazzoli, E., Zeybek, B., Han, C., Tymon‐Rosario, J., Altwerger, G. H., Menderes, G., Bianchi, A., et al. (2020) · Oncotarget · doi:10.18632/oncotarget.27342 · Cited by 51

Authors: Vogel, C. L., Cobleigh, M. A., Tripathy, D., Gutheil, J. C., Harris, L. N., Fehrenbacher, L., Slamon, D. J., Murphy, M., Novotny, W. F., Burchmore, M., Shak, S., Stewart, S. J., & Press, M.
Affiliations: University of Southern California (US)
ORCID: Cobleigh, Melody A.
Tripathy, Debu
Harris, Lyndsay N.
Fehrenbacher, Louis
Slamon, Dennis J.
Novotny, William F.
Shak, Steven
Press, Michael
Venue: Journal of Clinical Oncology
Publisher: American Society of Clinical Oncology (ASCO)
Published: 2002-02-01
Volume: 20
Issue: 3
Pages: 719-726
ISSN: 0732-183X (ISSN-L)
1527-7755
DOI: 10.1200/jco.2002.20.3.719
OpenAlex: W4239989216
Cited by: 1,860
References: 9
Citations by year: 2026: 12 · 2025: 34 · 2024: 52 · 2023: 75 · 2022: 113 · 2021: 67 · 2020: 72 · 2019: 62 · 2018: 97 · 2017: 95 · 2016: 87 · 2015: 88 · 2014: 71 · 2013: 91 · 2012: 74
FWCI: 32.63
Type: journal article
Language: en
Update notices: new_edition (2023-03-15)
Open access: closed
Locations: Journal of Clinical Oncology (publishedVersion)
Funders: National Cancer Institute (CA48780)
Topics: Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
Health Sciences › Medicine › Oncology › Gastric Cancer Management and Outcomes
Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
Keywords: trastuzumab, HER2-positive breast cancer, metastatic breast cancer, first-line therapy, single-agent chemotherapy, HER2 immunohistochemistry, HER2 amplification, objective response rate, adverse cardiac events, dose-response relationship, treatment safety

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Efficacy and Safety of Trastuzumab as a Single Agent in First-Line Treatment of HER2-Overexpressing Metastatic Breast Cancer

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks